Posts By :

Amy Swearingen

Chimeron Bio receives NIH (NCI) Innovative Concept Award for mRNA cancer vaccine development
Chimeron Recipient Innovative Concept Award

Chimeron Bio receives NIH (NCI) Innovative Concept Award for mRNA cancer vaccine development

Philadelphia, PA – Chimeron Bio, a Philadelphia-headquartered biotech company, has received a 2024 National Institutes of Health’s Small Business Innovation Research Innovative Concept Award through the National Cancer Institute. The funding will support Chimeron Bio’s program developing a cancer vaccine against an inherited form of colorectal cancer. Chimeron Bio will seek to develop a specialized…

read more
900 900 Chimeron Bio | Advancing Genetic Medicine
Chimeron Bio recognized by MilliporeSigma as a finalist in the Advance Biotech Grant Award

Chimeron Bio recognized by MilliporeSigma as a finalist in the Advance Biotech Grant Award

Philadelphia, PA – Chimeron Bio, a next generation RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary Multiplex delivery platform, announced today that the company has been recognized by MilliporeSigma as a finalist in the company's North American Advance Biotech Grant. As part of the award, Chimeron will receive in-kind products…

read more
750 750 Chimeron Bio | Advancing Genetic Medicine
Chimeron Bio Appoints Antonin de Fougerolles to its Board of Directors

Chimeron Bio Appoints Antonin de Fougerolles to its Board of Directors

Philadelphia, PA – Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery platform, announced today that Antonin (Tony) de Fougerolles had been appointed as the newest member of its Board of Directors. As the former founding CSO of Moderna, Tony is a pioneer in RNA…

read more
300 300 Chimeron Bio | Advancing Genetic Medicine
Chimeron Bio Welcomes Kevin Heyeck as New CEO

Chimeron Bio Welcomes Kevin Heyeck as New CEO

Philadelphia, PA – Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery platform, announced today that Kevin Heyeck had been named Chief Executive Officer. Kevin comes to Chimeron with a long and successful track record of executive and entrepreneurial experience in life sciences. Kevin began…

read more
300 300 Chimeron Bio | Advancing Genetic Medicine
Chimeron Bio Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its RNA Oncology Candidates

Chimeron Bio Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its RNA Oncology Candidates

Philadelphia, PA and College Station, TX – Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery platform, today announced it has entered into a manufacturing agreement with FUJIFILM Diosynth Biotechnologies (FDB), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and…

read more
206 206 Chimeron Bio | Advancing Genetic Medicine
Chimeron Bio Enters Into an Agreement with the NIAID, a Federal Agency, for Pre-clinical Assessment of its Self-Amplifying COVID-19 Vaccine

Chimeron Bio Enters Into an Agreement with the NIAID, a Federal Agency, for Pre-clinical Assessment of its Self-Amplifying COVID-19 Vaccine

Philadelphia, PA – Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESARTM RNA delivery platform, today announced it has signed a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to evaluate the…

read more
300 300 Chimeron Bio | Advancing Genetic Medicine
Chimeron Bio Expands Footprint in Philadelphia by Joining BioLabs at The Curtis

Chimeron Bio Expands Footprint in Philadelphia by Joining BioLabs at The Curtis

Philadelphia, PA – Chimeron Bio, a biotechnology company pioneering a novel class of self-amplifying RNA-vaccines and therapeutics announced its plan to expand operations in the Philadelphia area and move to The Curtis, a landmark site in Center City Philadelphia under BioLabs, the leading developer and operator of life science co-working spaces in the U.S. and…

read more
625 625 Chimeron Bio | Advancing Genetic Medicine